|Salary:||Competitive with benefits, subject to skills and experience|
|Placed On:||13th January 2021|
|Closes:||20th January 2021|
The closing date is on 20 January 2021 at 23.45.
This position is for a Senior Laboratory Research Scientist (SLRS) to oversee experimental operations and lead research projects in the Genome Function Laboratory led by Greg Findlay.
To date, tens of thousands of genetic variants in tumour suppressor genes have been deemed “variants of uncertain significance”, meaning it is unclear if they contribute to cancer development. This reflects how difficult it is to interpret the effects of rare variants in the human genome. While we have a foundational understanding of the genes and pathways that contribute to cancer, understanding precisely how different variants in those genes and nearby non-coding regions contribute to disease risk remains challenging.
Our lab deploys genome editing technologies to study the genetics of cancer, with the goal of understanding how every variant seen in a patient contributes to disease risk and treatment response. We implement CRISPR/Cas9-based assays such as Saturation Genome Editing and CRISPR guide RNA screening in human cells as means of cataloguing the functional effects of variants. We use readouts such as RNA sequencing, fluorescence reporter systems, cell growth, and drug selection to ask what effect each variant has on multiple levels of gene function. By performing this work in the context of the human genome, we are well-suited to discover variant effects on gene expression, RNA splicing, and protein function. The large data sets we produce will continue to prove highly valuable for guiding clinical decisions. Further, as we scale this work to millions of mutations, we will build a far more quantitative understanding of the basic genetic mechanisms underlying disease.
The Francis Crick Institute is a biomedical discovery institute dedicated to understanding the fundamental biology underlying health and disease. Its work is helping to understand why disease develops and to translate discoveries into new ways to prevent, diagnose and treat illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases.
An independent organisation, its founding partners are the Medical Research Council (MRC), Cancer Research UK, Wellcome, UCL (University College London), Imperial College London and King’s College London.
The Crick was formed in 2015, and in 2016 it moved into a new state-of-the-art building in central London which brings together 1500 scientists and support staff working collaboratively across disciplines, making it the biggest biomedical research facility under in one building in Europe.
The Francis Crick Institute will be world-class with a strong national role. Its distinctive vision for excellence includes commitments to collaboration; developing emerging talent and exporting it the rest of the UK; public engagement; and helping turn discoveries into treatments as quickly as possible to improve lives and strengthen the economy.
Type / Role: